Page 16 - Clinical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Acurx Pharmaceuticals Inc. continues to post positive data for its lead candidate ibezapolstat but that didn’t stop the stock from tumbling. The antibiotic outperformed vancomycin in a phase IIb study treating Clostridioides difficile infection (CDI). Vancomycin is a standard of care in the indication. Ibezapolstat eradicated fecal CDI at day 3 in 15 of 16 patients compared to vancomycin, which eradicated fecal CDI in 10 of 14 patients.

Allakos Inc. terminated all development of its lead drug, anti-Siglec-8 antibody lirentelimab (AK-002), and is cutting its workforce in half, following phase II failures for atopic dermatitis and chronic spontaneous urticaria. The San Carlos, Calif.-based company will now focus on phase I trials for anti-Siglec-6 antibody AK-006 as part of a restructuring that stretches the runway into mid-2026. Shares (NASDAQ:ALLK) sank by 60.2%, down $1.80, to close at $1.19 on Jan. 16.

>> most participants taken >> most participants taken before guard also haou. less muscle weakness, and you have been off guard treatment scheduleed is designed just for you in a clinical. y of i the most common side effects included and respiratory tract infectionsnf and headache. this guard may increase the risk of infection. the risk of infection. tell your doctor ailabl if you haveon. a history of infections or symptoms of an infection, this guard can cause allergic reactions available as guard for i.v infusion and also as vive guard. >> hi true low for subcutaneous >> hi true low for subc...

Nature of Pat Hoban’s exit from Dundalk provides a new dimension to Derry City’s challenge.

Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.